Accufix

What Accufix does

Accufix Surgical is a privately-held specialty orthopedic medical device company developing and commercializing the FDA-approved Accu-Joint® Hemi Implant System for treatment of metatarsophalangeal (MTP) joint disorders, including hallux limitus, hallux rigidus, hallux valgus, and degenerative or post-traumatic arthritis of the big toe. The company targets board-certified orthopedic surgeons and podiatric physicians specializing in foot and ankle surgery, with a downstream patient population seeking alternatives to irreversible joint fusion. Headquartered in West Haven, Connecticut, Accufix is a Delaware-incorporated entity (Accufix Holdings, Inc.) that employs 1–10 people and operates a sales-led go-to-market model combining a direct field sales organization with a distributor network.

The Accu-Joint® system is a hemi-arthroplasty implant available in metatarsal head and phalangeal base configurations. Its technical differentiation rests on four design pillars: (1) a non-weight-bearing architecture in which the implant is sized 10–15% smaller than the bone end so the patient's existing anatomy—not the implant—bears body weight; (2) minimal bone resection of approximately 1mm via patented resurfacing instruments, versus 5mm or more removed by traditional resection implants, preserving bone stock for future interventions; (3) a solid stem with cancellous threads and a threaded barrel that transfers stress to subchondral bone, plus grooved and scalloped edges enabling bone ingrowth to prevent loosening; and (4) a patent-protected two-stage reamer for joint surface preparation. The company holds six granted US patents covering the implant, instrumentation, and surgical methodology, and operates under FDA 510(k) clearance (K201234) granted December 8, 2020.

Revenue is generated through one-time hardware sales of single-use implants to healthcare providers, with the device intended for use with bone cement during MTP joint procedures. Pricing is not publicly disclosed and is negotiated through institutional purchasing and distributor relationships. The go-to-market combines a direct field sales team (VP of Sales Robert Torney, Area Vice President West David Dodson) with a distributor channel that includes Academy Medical for federal/VA procurement and a broader 'For Distributors' program, while Disruptive MedTech serves as the contract manufacturing partner. The company has raised approximately $5.2 million cumulatively across disclosed rounds, including a 2022 SEC Form D exempt offering of $3.93 million (with $3.65 million sold) and a $1.5 million round led by Minnow Ventures in July 2022.

Name

Accufix

Legal name

Accufix Surgical, Inc.

Website

https://accufixsurgical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Accufix Surgical is a private orthopedic device company that markets the FDA-approved Accu-Joint® Hemi Implant for treating MTP joint disorders such as hallux limitus and hallux rigidus. It sells its bone-preserving resurfacing implant to orthopedic surgeons and podiatrists across the United States.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)

Keywords

• Orthopedic implants
• MTP joint resurfacing
• Foot and ankle surgery
• Hemi arthroplasty devices
• Toe joint replacement

Headquarters

HQ city

West Haven

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Accu-Joint® Hemi Implant Sales: One-time sale of medical implants to healthcare providers (surgeons/hospitals). The implant is a single-use device intended for surgical procedures to treat MTP joint disorders. Revenue is generated per unit sold, with the product used with bone cement during surgery.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Accufix Surgical develops, manufactures, and distributes the FDA-approved Accu-Joint® Hemi Implant System, a hemi-arthroplasty medical device for the metatarsophalangeal (MTP) joint that resurfaces worn articular cartilage while preserving subchondral bone as an alternative to joint fusion or full resection implants. The system includes the Accu-Joint® Hemi Implant (metatarsal head and phalangeal base variants) and patented instrumentation such as the 2-Stage MTP Joint Reamer, sold as a single-use device for orthopedic surgeons and podiatrists treating hallux limitus, hallux rigidus, hallux valgus, and other degenerative or post-traumatic MTP joint conditions.

Product overview

Accufix Surgical is a specialty orthopedic device company offering a single unified product line: the Accu-Joint® Implant System. The primary offering is the Accu-Joint® Hemi Implant, a hemi-arthroplasty device for MTP joint disorders that preserves bone and replaces cartilage through a resurfacing approach rather than resection or fusion. The company positions itself as an alternative to joint fusion surgery, emphasizing joint preservation over joint replacement. The product portfolio consists of one core implant system available in metatarsal head and phalangeal base configurations.

Differentiator

Problem solved

Functional benefit

Products and services

• Accu-Joint® Hemi Implant System FDA-approved hemi-arthroplasty implant system for metatarsophalangeal (MTP) joint disorders, sold as a single-use device to orthopedic surgeons and podiatrists for use with bone cement. The implant is sized 10–15% smaller than the bone end so the patient's existing anatomy bears body weight, features a solid stem with cancellous threads and a threaded barrel for stress transfer, and has grooved/scalloped edges for bone ingrowth to prevent loosening. Patented instruments resurface the bone end by removing only cartilage and approximately 1mm of bone. Available in metatarsal head and phalangeal base configurations.

Quantifiable outcome

• Only 1mm of bone resection vs. 5mm+ for traditional implants
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Academy MedicalcoreChannel Partner/ Reseller/ DistributorAcademy Medical is a veteran and industry expert-led team helping the federal procurement community access medical devices. They provide distribution access to government healthcare facilities including VA hospitals and military medical centers.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Stryker (Cartiva): Acquired Cartiva in 2018 — Cartiva's synthetic cartilage implant is the most directly comparable big-toe (MTP) hemi-arthroplasty product on the US market, targeting the same hallux rigidus / hallux limitus patient population as Accu-Joint.
• Arthrosurface: Develops small-joint hemi / resurfacing implant systems, including for the toe and foot, using a similar philosophy of bone-preserving articular surface replacement — the closest architectural analog to the Accu-Joint Hemi Implant.
• Paragon 28: Pure-play foot & ankle surgical company offering forefoot, midfoot, and small-joint implant solutions to the same podiatric and orthopedic foot & ankle surgeon base that Accufix targets.
• Vilex: Specialty orthopedic company focused on small bone and extremity surgery, with toe and forefoot implant offerings aimed at the same foot & ankle surgeon channel as Accufix.
• Extremity Medical: Develops implants and instruments specifically for distal extremity and foot & ankle surgery, including forefoot and MTP joint products, directly competing for the same surgeon mindshare and OR shelf space.

Broad incumbents

• Wright Medical (now Stryker Foot & Ankle): Historically the dominant foot & ankle reconstruction franchise; offers a broad portfolio including toe implants and MTP arthroplasty options, and now backed by Stryker's distribution scale across the same surgeon call points as Accufix.
• In2Bones (Conmed): Foot & ankle and upper extremity specialist (now part of Conmed) that markets forefoot/MTP implants and biologic solutions to the same podiatric and orthopedic foot & ankle call points.
• Arthrex: Largest extremities-focused orthopedic company with a broad foot & ankle portfolio; competes less on a single toe implant but shapes the standard of care, training, and surgeon relationships in the same procedures.
• DePuy Synthes (Johnson & Johnson): Broad orthopedic incumbent offering foot & ankle and extremities solutions; provides the alternative of fusion hardware and full-joint replacement systems that Accufix competes against in MTP procedures.
• Tornier (now Stryker): Extremities-focused franchise (folded into Stryker) historically active in small-joint arthroplasty and foot & ankle reconstruction, representing the kind of strategic acquirer most likely to consolidate Accufix-class technology.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/accufix-surgical
• Facebookfacebook.com/AccufixSurgical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accufix